Superpower peptides available for pre-order. Get first access.
Not FDA-approved
Digestive & weight
What are the side effects of BPC-157?
See which BPC-157 side effects have been reported, what animal and human safety studies found, how product quality matters, and when to call a clinician.
Quick answer
BPC-157 is not FDA-approved, has no established labeled route, and has no established human side-effect profile. Safety data come mostly from animals and a few small human studies, which reported no treatment-related adverse events. FDA's drug adverse-event database held three reports through early December 2025: injection-site redness and swelling, shortness of breath, and skin and gum darkening. FDA could not confirm that BPC-157 caused any of them. Spreading redness or fever warrants calling the prescribing clinician, while facial swelling or wheezing needs emergency care. WADA prohibits BPC-157 at all times.
- Published
- November 4, 2026
- Last updated
- November 4, 2026
What BPC-157 side effects have been reported?
BPC-157 side effects come from a few adverse-event reports and small human studies1. Most BPC-157 safety findings come from animal research2.
Through early December 2025, FDA's drug adverse-event database held three BPC-157 reports3, all with injected products. FDA could not confirm that BPC-157 caused any of them.
- Injection-site redness and swelling: One report described nine days of redness and swelling in a person also injecting compounded thymosin.
- Shortness of breath: One report described shortness of breath leading to an emergency room visit after subcutaneous (under-the-skin) BPC-157 acetate.
- Skin and gum darkening: One report described this darkening with a subcutaneous product combining BPC-157 and TB-500. The darkening returned on reuse and stopped after discontinuation3. Because the product held two peptides, FDA could not assess BPC-157's role.
Outside those reports, meeting abstracts from enema studies in healthy volunteers listed headache and flatulence3 as the most frequent adverse events.
Reports like these help flag concerns, but they do not show how often an effect occurs or prove its cause. FDA also does not receive every report3 on compounded products, since compounding pharmacies generally do not file them. Studies add a more structured view.
What do studies show about BPC-157 safety?
BPC-157 showed no serious toxicity in animal studies. A systematic review of human data found three small studies covering 30 people1, a starting point rather than a full human side-effect profile.
A safety program in mice, rats, rabbits, and dogs2 is one reason BPC-157 is often described as well tolerated. FDA's review of 28-day rat and dog studies also noted liver-related blood changes3, including raised ALT (a liver enzyme). Both results describe animals, not people.
The three human studies tested knee injections, injections into the bladder wall, and an intravenous pilot in two adults4. None reported treatment-related adverse events. Each used one route, so none describes subcutaneous or oral use.
These studies describe the material researchers tested, so the product itself also matters.
BPC-157 product quality and safety
Product quality shapes BPC-157 safety, because peptides are sensitive to formulation, process, and storage3.
- Immune reactions: Formulation and storage can create peptide clumps that may trigger immune responses3.
- Impurities: Compounded BPC-157 may carry peptide-related impurities5 and an active ingredient that is hard to characterize.
- Sterility: For injected BPC-157, sterility, bacterial toxins, and particles are critical safety attributes3.
- Contamination: Unregulated manufacturing and contamination6 are possible causes of BPC-157 adverse effects.
A reaction may stem from the peptide, the product, or the injection, which makes warning signs worth knowing.
How can BPC-157 side effects be managed?
New symptoms after BPC-157 are worth raising with the prescribing clinician, while a severe allergic reaction needs emergency care right away7.
- Watch the injection site: Unlike a brief local reaction, skin infection brings spreading redness, warm skin, tenderness, and fever8.
- Keep a record: Noting when a symptom started, how long it lasted, and the product and route helps the clinician judge it.
- Contact the prescribing clinician: Infection signs warrant a call right away8, and any other new symptom is worth raising too. Patients can also report a reaction to FDA9.
- Get emergency care: Wheezing, chest tightness, hives, facial swelling, or a swollen tongue can start within minutes7 and call for 911 or an emergency room.
A few health factors are worth reviewing before a first dose.
Who should talk to a clinician first?
Some health factors call for an individual review with the prescribing clinician first. They reflect animal findings and areas not yet studied, not proven harm in people.
| Before using BPC-157, discuss | Why it matters |
| Pregnancy or breastfeeding | A rat study found no fetal effects, but no study has covered a full reproductive cycle3 |
| Cancer or unexplained growths | BPC-157 increased blood-vessel growth signaling in lab and animal models10, and no cancer-risk studies have been identified3, a reason for an individual risk review |
| Medicines and upcoming procedures | Animal studies showed changes in clotting times3, which a clinician can weigh against blood thinners, surgery, or dental work |
Competitive athletes also have sport rules to consider.
WADA prohibits BPC-157 at all times11 as a non-approved substance (class S0) on its 2026 Prohibited List. Athletes subject to drug testing can face sanctions, so current WADA and league rules are worth checking first.
Getting BPC-157 in 2026
Superpower will offer BPC-157 formulated in FDA-registered facilities in the US, backed by third-party lab testing, and distributed from US-licensed pharmacies. A licensed clinician will review each person's health history to decide whether BPC-157 fits their health care. The Superpower peptide waitlist is open now.
BPC-157 is not an FDA-approved drug. The Department of Health and Human Services announced in October 2026 that it does not intend to take enforcement action12 against state-licensed pharmacies that compound BPC-157 while the 503A Bulks List, the roster of ingredients pharmacies may use in compounding, is finalized. Six peptides fall under that interim policy13, BPC-157 among them, and its conditions include a patient-specific prescription and ingredients from FDA-registered facilities. A July 2026 FDA advisory committee had recommended adding BPC-157 to the list14, and rulemaking is not yet complete.